FDA Approves BAQSIMI, The First and Only Nasally Administered Glucagon to Treat Severe Hypoglycemia

[Northerner]

The U.S. Food and Drug Administration (FDA) has approved Lilly’s BAQSIMI (glucagon) nasal powder 3 mg for the treatment of severe hypoglycemia in people with diabetes ages four years and above. BAQSIMI is the first and only nasally administered glucagon, and it was designed with severe hypoglycemia rescue in mind.

https://asweetlife.org/fda-approves-baqsimi-the-first-and-only-nasally-administered-glucagon-to-treat-severe-hypoglycemia/